Welcome to our dedicated page for Vyome Holdings SEC filings (Ticker: HIND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Vyome Holdings, Inc. (NASDAQ: HIND) filings with the U.S. Securities and Exchange Commission, along with AI-powered tools that help interpret the information. Vyome is a clinical-stage healthcare holding company focused on immuno-inflammatory conditions, AI-driven health applications, and AI-enabled medical devices, and its SEC filings offer structured detail on these activities.
Investors can review current reports on Form 8-K, where Vyome discloses material events such as its streamlined Nasdaq listing, financial results for reporting periods, and transactions like the acquisition of substantially all assets of Oculo, Inc. or the announcement of a binding letter of intent involving LiveChain, Inc. and Humanyze. These filings also confirm that Vyome’s common stock, par value $0.001 per share, is listed on The Nasdaq Capital Market under the symbol HIND and that the company qualifies as an emerging growth company.
The definitive proxy statement on Schedule 14A (DEF 14A) is another key document. It describes matters submitted to stockholders at the annual meeting, including the election of Class I directors, approval of the Vyome Holdings, Inc. 2025 Equity Incentive Plan, ratification of the independent registered public accounting firm, and advisory votes on executive compensation. The proxy statement also outlines governance structures and provides context on how the board oversees Vyome’s strategy.
Through this page, users can quickly locate Vyome’s quarterly and annual reports when available, as well as any future registration statements, proxies, or additional 8-Ks that discuss clinical progress for VT-1953 and other programs, capital structure details, or changes in governance. AI-generated summaries highlight the main points in lengthy documents, helping readers understand how specific items—such as equity plans, material transactions, or board decisions—relate to Vyome’s broader focus on immuno-inflammation, AI initiatives, and the US–India innovation corridor.
Vyome Holdings, Inc. reported an equity award to a company director in connection with its merger with Vyome Therapeutics, Inc. Following the August 15, 2025 merger, outstanding Vyome Therapeutics stock options were assumed and converted into options over Vyome Holdings common stock.
Under this structure, the reporting person received options to purchase 624,432 shares of Vyome Holdings common stock at an exercise price of $0.66 per share, granted on November 13, 2025. These options were fully vested on the grant date and were issued under the company’s 2025 Equity Incentive Plan. The filing reflects the director’s beneficial ownership of these derivative securities rather than an open-market share purchase or sale.
Vyome Holdings, Inc. (HIND) filed a Form 3 reporting that director Shiladitya Sengupta currently has no beneficial ownership of the company’s securities. This initial statement of beneficial ownership is triggered by an event dated 08/15/2025 and confirms that, as of that date, the director did not hold any non-derivative or derivative securities of Vyome Holdings.
Vyome Holdings, Inc. reported an option grant to its President and CEO, Venkat Nelabhotla, who also serves as a director. On 11/13/2025 he received stock options to purchase 615,149 shares of Vyome Holdings common stock at an exercise price of $0.66 per share, and these options were fully vested on the grant date under the company’s 2025 Equity Incentive Plan.
The filing also explains that, under a previously signed Merger Agreement, Raider Lifesciences Inc. merged into Vyome Therapeutics, Inc. on August 15, 2025, with Vyome Therapeutics becoming a subsidiary of the issuer. Following this transaction, the issuer was renamed Vyome Holdings, Inc., while Vyome Therapeutics continued as Vyome Therapeutics, Inc.
Vyome Holdings, Inc. (HIND) filed a Form S-8 with a reoffer prospectus registering up to 1,524,918 shares of common stock issuable under the 2025 Equity Incentive Plan for potential resale by certain selling stockholders. The filing states the company will receive no proceeds from any resales; it would receive cash only if option holders exercise options for cash, with any such proceeds used for general corporate purposes.
The reoffer allows periodic sales on Nasdaq or in negotiated transactions subject to Rule 144(e) limits. The selling group includes executives and directors, including Krishna Gupta 249,671 and Venkat Nelabhotla 615,149. Shares outstanding were 5,644,394 as of November 10, 2025. The stock trades on the Nasdaq Capital Market under the symbol HIND.
Vyome Holdings, Inc. (HIND) filed a resale registration for 610,185 shares of common stock to permit sales by identified selling stockholders from time to time. The company will not receive any proceeds from these sales and will cover registration expenses, while selling holders bear brokerage fees and commissions.
The shares may be sold through various methods on Nasdaq or in private transactions as described in the plan of distribution. Shares outstanding were 5,630,509 as of November 3, 2025; this is a baseline figure, not the amount being registered.
The prospectus notes Vyome’s recent merger and name change, a 1‑for‑4 reverse stock split on August 15, 2025, and an at‑the‑market program previously amended to allow up to $12,000,000 of sales, which are separate from this resale.
Vyome Holdings (HIND) reported results of its 2025 Annual Meeting of Stockholders. A quorum of 4,258,856 shares, representing 77.52% of shares outstanding and eligible to vote, was present in person or by proxy.
Stockholders elected Krishna K. Gupta, Shiladitya Sengupta and Stash Pomichter as Class I directors to serve until the 2028 annual meeting. The 2025 Equity Incentive Plan was approved with 3,766,413 votes for, 184,403 against, and 6,600 abstentions, with 301,440 broker non-votes. Stockholders ratified Kreit & Chiu CPA LLP as independent auditor for the fiscal year ending December 31, 2025 with 4,248,216 votes for, 10,081 against, and 559 abstentions.
On a non-binding advisory basis, compensation of named executive officers was approved with 3,945,592 votes for, 11,052 against, 772 abstentions, and 301,440 broker non-votes.
Vyome Holdings, Inc. filed a Definitive Proxy Statement (DEF 14A) describing items for its annual meeting, including four proposals: the election of three Class I directors, approval of an equity Plan, ratification of the auditor, and an advisory vote on executive compensation. The filing lists nominees Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter for three-year terms and profiles key executives including CEO Venkat Nelabhotla and CFO Robert Dickey.
The proxy explains voting mechanics for shares held in street name, noting that brokers cannot vote on certain non-routine proposals without instructions, which may lead to broker non-votes. It discloses related-party consulting payments (e.g., Dr. Sengupta: $100,000 per annum and $151,939 in VTI stock awards for 2024), director compensation retainers, stockholder proposal deadline of June 30, 2026, and prior material weaknesses in internal control reported in the Company’s Form 10-K for fiscal years 2023 and 2022.
Vyome Holdings, Inc. (HIND) announced it acquired Oculo, Inc. On September 29, 2025, the company reported the purchase of Oculo, an AI startup launched at the Massachusetts Institute of Technology. The announcement was made under Other Events, with a press release furnished as Exhibit 99.1.
This move signals Vyome’s interest in artificial intelligence capabilities originating from MIT’s ecosystem. Additional details are provided in the attached press release referenced in the filing.
Vyome Holdings Form 4: This Form 4 reports that Venkat Nelabhotla, President, CEO and a director, received 7 shares of Vyome Holdings common stock as a result of a merger on 08/15/2025. Under the Merger Agreement, each 5,000 shares of Vyome Therapeutics common stock converted into 1 share of Vyome Holdings common stock. The reporting person exchanged 35,000 Vyome Therapeutics shares and received 7 Vyome Holdings shares. The Form 4 was filed as a single reporting person and is signed on 09/22/2025.
John M. Tincoff III filed an initial Form 3 reporting his relationship to Vyome Holdings, Inc. (ticker shown in the filing as HIND) as a Director. The event date is 08/15/2025. The filing states no securities are beneficially owned by the reporting person. The form is signed and dated 09/18/2025.